Jeffrey Goldberg
About Jeffrey Goldberg
Jeffrey Goldberg (age 59) was appointed as an independent, non-employee director of Modular Medical (MODD) on May 22, 2025. He holds a J.D. from UCLA School of Law and an A.B. in Philosophy from Harvard College, and brings extensive board leadership experience across healthcare and technology companies. Tenure on this board began May 2025; the company disclosed no related-party transactions involving Goldberg and indicated he would sign the standard indemnification agreement .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| ATI Physical Therapy, Inc. | Director | Since Dec 2023 (current) | Public company board experience; healthcare services |
| Lannett Company, Inc. | Chairman/Director | Current | Press release cites Chair role; generic insulin development oversight; turnaround leadership |
| Eating Recovery Centers/Pathlight | Director | Current | Behavioral health exposure |
| Banza | Director | Current | Consumer/CPG experience |
| Cano Health | Director | Current (press release) | Primary care operations oversight (press release disclosure) |
| IncuMed (Alfred E. Mann incubator) | President & CEO (portfolio leadership) | Prior | Led drug-device combination initiatives incl. insulin patch-pump; regulatory/ops turnarounds |
External Roles
| Company | Public/Private | Role | Notes |
|---|---|---|---|
| ATI Physical Therapy, Inc. | Public | Director | Appointed Dec 2023 |
| Lannett Company, Inc. | Private/Public transition | Chairman/Director | Press release identifies Chair role; generic insulin program |
| Eating Recovery Centers/Pathlight | Private | Director | Behavioral health |
| Banza | Private | Director | Food/CPG |
| Cano Health | Public (at time of press release) | Director | Primary care; press release disclosure |
Board Governance
- Committee assignments: As of the FY2025 10-K, committees were composed of Felsher/Sheibley/Volkart (Audit), DeSisto/Volkart (Compensation), Sheibley/Felsher (Nominating & Governance). Goldberg was not listed on any committee at that time .
- Independence: The board determined all current directors other than DiPerna, Frank, and Vos are independent under Nasdaq/SEC rules; Goldberg qualifies as independent .
- Attendance/engagement: Goldberg joined in May 2025; no attendance data yet disclosed for him. In FY2024, all directors then serving met at least 75% attendance; Board held two meetings (context, not specific to Goldberg) .
- Hedging policy: Officers and directors are prohibited from engaging in short sales of company securities .
Fixed Compensation
| Element | Amount/Terms | Source |
|---|---|---|
| Annual cash retainer (Board) | $25,000, paid quarterly; director may elect cash, options or shares | |
| Committee chair fee | $5,000 per committee chair, paid quarterly; same election choices | |
| Annual service equity award | $100,000 in equity, paid quarterly in options or shares at director’s election (minimum $10/share used to calculate award size) | |
| New director equity award | Equity grant under 2017 Plan upon appointment; vests over 3 years | |
| Participation | Goldberg is eligible under the Outside Director Compensation Plan |
Note: The company’s 8-K did not disclose a specific grant size for Goldberg at appointment; his Form 3 reported no beneficial ownership as of May 30, 2025 .
Performance Compensation
| Feature | Details | Source |
|---|---|---|
| Performance-conditioned components | None disclosed for outside directors; awards are time-based equity and retainer mix | |
| Clawback policy | Company has a compensation recovery policy applicable to executive officers (context); no director-specific performance metrics disclosed |
Other Directorships & Interlocks
- Current boards include ATI Physical Therapy, Eating Recovery/Pathlight, Lannett, Banza (8-K) and Cano Health (press release) .
- Potential sector proximity: Lannett’s work on generic insulin could place Goldberg in proximity to a diabetes-therapy supply chain. The company disclosed no related-party transactions involving Goldberg and no arrangements related to his appointment .
- Monitoring point: Any future commercial dealings with entities where Goldberg serves should be reviewed for conflicts.
Expertise & Qualifications
- Education: J.D., UCLA School of Law; A.B., Harvard College .
- Domain expertise: Healthcare services, medical devices, and drug-device combinations; prior leadership within Alfred Mann’s incubator on insulin patch-pump and regulatory/operational turnarounds .
- Board/leadership: Experience as board chair and director across multiple companies, including turnaround contexts .
Equity Ownership
| Item | Detail | Source |
|---|---|---|
| Beneficial ownership (initial) | Form 3 filed May 30, 2025 reported no securities beneficially owned | |
| Ownership guidelines/pledging | No director ownership guidelines or pledging disclosures specific to Goldberg; company prohibits short sales by officers/directors |
Governance Assessment
-
Positives
- Independent director with deep healthcare and medtech governance experience; no related-party transactions disclosed; standard indemnification in place .
- Director pay structure emphasizes equity ($100k annual equity grant), fostering alignment with shareholders over time .
- Sector knowledge (drug-device, insulin) may enhance board oversight of commercialization strategy .
-
Watch items / RED FLAGS to monitor
- Interlock proximity: Lannett’s generic insulin efforts may intersect with MODD’s diabetes ecosystem; while no related transactions exist, any future dealings should be evaluated for conflicts and recusal as needed .
- Alignment ramp-up: Initial Form 3 reported no holdings; ensure timely disclosure of any director equity awards/ownership to evidence alignment over time .
- Committee participation: Not assigned to a committee as of FY2025 10-K; adding him to relevant committees (e.g., Nominating & Governance, Strategy/Commercialization oversight) could leverage his experience .